Kurs nähert ich unaufhaltsam der 5,40$.. Dann ist wohl erstmal Pause
Top-News
Neuester,
zuletzt geles. Beitrag
Antworten | Börsenforum Übersicht
Zurück
Weiter
1 2 3 5 6 7 8 9 10 ...
Antworten | Börsenforum Übersicht
Zurück
Weiter 1 2 3 5 6 7 8 9 10 ...
Neustart mit "frischem Kapital"
Beiträge: 275
Zugriffe: 105.719 / Heute: 141
Zugriffe: 105.719 / Heute: 141
|
Werbung
Entdecke die beliebtesten ETFs von Amundi
Lyxor Net Zero 2050 S&P World Climate PAB (DR) UCITS ETF Acc
Perf. 12M: +206,18%
Amundi Nasdaq-100 Daily (2x) Leveraged UCITS ETF - Acc
Perf. 12M: +82,31%
Amundi ETF Leveraged MSCI USA Daily UCITS ETF - EUR (C/D)
Perf. 12M: +64,89%
Amundi Japan TOPIX II UCITS ETF - EUR Hedeged Dist
Perf. 12M: +40,67%
Amundi MSCI India II UCITS ETF - EUR Acc
Perf. 12M: +38,52%
Dann doch noch zurück gen 5,40$
seekingalpha.com/symbol/AGEN/...ocus&news_tab=latest-news
seekingalpha.com/symbol/AGEN/...ocus&news_tab=latest-news
so viele grüne Kerzen gesehen :)
(Verkleinert auf 59%) 
würde es durchaus Sinn machen nochmal auf das Ausbruchslevel (~5,45) zu fallen.
Dann auf längere Sicht 10,-$ angesagt
Dann auf längere Sicht 10,-$ angesagt
(Verkleinert auf 39%)
Erst über die 6 Dollar hochgezogen....
Dann wurde scheinbar eine SL-Welle ausgelöst ,
um zurück " Auf Start " zu landen :-(
Trotz alledem bin ich überzeugt,
dass wir in naher Zukunft die 6 Dollar nachhaltig hinter uns lassen :-)
Jetzt kommt der Moment wo der Elefant das Wasser lässt..
Spätestens am 15.03. (zu den Zahlen) hopp oder topp.
Über 5,45 bleiben !!
Spätestens am 15.03. (zu den Zahlen) hopp oder topp.
Über 5,45 bleiben !!
Agenus Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
de.advfn.com/p.php?pid=nmona&article=76954190
de.advfn.com/p.php?pid=nmona&article=76954190
de.advfn.com/p.php?pid=nmona&article=76970539
Bin hier zum Glück rechtzeitig Mitte März raus. Jetzt sollte man mal schauen was der Grund für den Verfall war/ist und neu bewerten. Hat mich gerade ein netter Kollege drauf aufmerksam gemacht.
--
Erst mal den Cash-Bestand herausfinden.
Hier die aktuelle Präsentation.
investor.agenusbio.com/presentation-webcasts?item=37
--
Erst mal den Cash-Bestand herausfinden.
Hier die aktuelle Präsentation.
investor.agenusbio.com/presentation-webcasts?item=37
(Verkleinert auf 39%)
Aus dem Jahresbericht 2017:
"..On December 31, 2017, we had $60.2 million in cash and cash equivalents and short-term investments. We believe that, based on our current plans and activities, including additional funding we anticipate from multiple sources between now and the end of the second quarter of 2018, including outlicensing and/or partnering opportunities, our working capital resources at December 31, 2017, along with the net proceeds of approximately $28.0 million received from HCR in January 2018 in connection with our royalty transaction, will be sufficient to satisfy our liquidity requirements through the first quarter of 2019.."
investor.agenusbio.com/sec-filings
Seite 15
Das hier ist auch interessant..
"..Our net losses for the years ended December 31, 2017, 2016, and 2015, were $120.7 million, $127.0 million, and $87.9 million, respectively. We expect to incur additional losses over the next several years as we continue to research and develop our technologies and pursue partnering opportunities, regulatory strategies, commercialization, and related activities. Furthermore, our ability to generate cash from operations is dependent on the success of our licensees and collaboration partners, as well as the likelihood and timing of new strategic licensing and partnering relationships and/or successful development and commercialization of product candidates, including through our antibody programs and platforms, our vaccine programs, and our saponinbased vaccine adjuvants..."
"..On December 31, 2017, we had $60.2 million in cash and cash equivalents and short-term investments. We believe that, based on our current plans and activities, including additional funding we anticipate from multiple sources between now and the end of the second quarter of 2018, including outlicensing and/or partnering opportunities, our working capital resources at December 31, 2017, along with the net proceeds of approximately $28.0 million received from HCR in January 2018 in connection with our royalty transaction, will be sufficient to satisfy our liquidity requirements through the first quarter of 2019.."
investor.agenusbio.com/sec-filings
Seite 15
Das hier ist auch interessant..
"..Our net losses for the years ended December 31, 2017, 2016, and 2015, were $120.7 million, $127.0 million, and $87.9 million, respectively. We expect to incur additional losses over the next several years as we continue to research and develop our technologies and pursue partnering opportunities, regulatory strategies, commercialization, and related activities. Furthermore, our ability to generate cash from operations is dependent on the success of our licensees and collaboration partners, as well as the likelihood and timing of new strategic licensing and partnering relationships and/or successful development and commercialization of product candidates, including through our antibody programs and platforms, our vaccine programs, and our saponinbased vaccine adjuvants..."
kam am 15./16.03.2018, und am 19.03. begann dann der Kursverfall.
(s.auch #84)
(s.auch #84)
kamen gestern... erstmal -10%, heute dann + 7%
Und das genau an der "Wendemarke". (3,06$). Nicht schlecht
www.nasdaq.com/article/...-than-expected-shares-down-cm960505
Und das genau an der "Wendemarke". (3,06$). Nicht schlecht
www.nasdaq.com/article/...-than-expected-shares-down-cm960505
Agenus Discovery Enhances Activity of Cancer Fighting Antibodies; Findings Published in Cancer Cell
Dienstag, 12.06.2018 14:35 von PR Newswire
PR Newswire
LEXINGTON, Mass., June 12, 2018
LEXINGTON, Mass., June 12, 2018 /PRNewswire/ -- A study published in Cancer Cell reports on a novel discovery made by Agenus Inc. (NASDAQ: AGEN) that may enhance the immune activity of cancer fighting antibodies, including those targeting CTLA-4. Agenus has applied this discovery to its proprietary next generation anti-CTLA-4 antibody (AGEN1181) on track for IND filing in 2H2018.
Agenus Logo
The pre-clinical study reports on a unique mechanism discovered by Agenus, that can significantly improve the biological and immunological activity of certain cancer fighting antibodies, such as those targeting CTLA-4 and TIGIT. These findings provide the foundation for developing "next generation" (next-gen) antibodies designed to improve performance and expand clinical benefit. Agenus has already employed this novel discovery to make next-gen monospecific and bispecific antibodies that are on target for IND filings this year and early next year.
"We have discovered a new mechanism involving a key portion of antibodies that modulates biological function and cancer fighting abilities," said Dr. Jeremy Waight, Principal Scientist at Agenus and lead author of the study. "Based on our discovery, we can modify this region, known as the Fc region, to significantly improve an antibody's biological activity, by improving its immunological activity. We have already applied this discovery to our next generation anti-CTLA-4 antibody as well as other monospecific and bispecific antibodies in our pre-clinical pipeline and observed dramatic improvement in immune responses and anti-tumor activity."
Specifically, the research team demonstrated that a change in the Fc region can significantly improve the cross-talk between two immune cell types, such as antigen presenting cells (APCs) and T cells. This modification in the Fc region increases the duration and strength of interaction between the immune cells. In cancer immunotherapy, such an interaction is necessary to mount a potent immune response against cancer.
"These findings are at the core of our next-generation antibody programs, which have moved at an incredible speed from the drawing boards to being clinic ready in about 15 months, a testament to our strategy built on innovation and speed," said Alex Duncan, PhD, Chief Technology Officer and Head of Research. "These findings provide a foundation for developing best-in-class antibodies optimized to improve response rates and durability of response for patients with cancer."
For more details please see the publication here www.cell.com/cancer-cell/fulltext/S1535-6108(18)30219-8.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing a number of combination approaches that leverage a broad repertoire of antibody therapeutics and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com; information that may be important to investors will be routinely posted on our website.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the Company's planned IND filings and the enhanced function of certain antibodies in the Company's pipeline. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
Cision View original content with multimedia:www.prnewswire.com/news-releases/...cancer-cell-300664692.html
SOURCE Agenus Inc.
Dienstag, 12.06.2018 14:35 von PR Newswire
PR Newswire
LEXINGTON, Mass., June 12, 2018
LEXINGTON, Mass., June 12, 2018 /PRNewswire/ -- A study published in Cancer Cell reports on a novel discovery made by Agenus Inc. (NASDAQ: AGEN) that may enhance the immune activity of cancer fighting antibodies, including those targeting CTLA-4. Agenus has applied this discovery to its proprietary next generation anti-CTLA-4 antibody (AGEN1181) on track for IND filing in 2H2018.
Agenus Logo
The pre-clinical study reports on a unique mechanism discovered by Agenus, that can significantly improve the biological and immunological activity of certain cancer fighting antibodies, such as those targeting CTLA-4 and TIGIT. These findings provide the foundation for developing "next generation" (next-gen) antibodies designed to improve performance and expand clinical benefit. Agenus has already employed this novel discovery to make next-gen monospecific and bispecific antibodies that are on target for IND filings this year and early next year.
"We have discovered a new mechanism involving a key portion of antibodies that modulates biological function and cancer fighting abilities," said Dr. Jeremy Waight, Principal Scientist at Agenus and lead author of the study. "Based on our discovery, we can modify this region, known as the Fc region, to significantly improve an antibody's biological activity, by improving its immunological activity. We have already applied this discovery to our next generation anti-CTLA-4 antibody as well as other monospecific and bispecific antibodies in our pre-clinical pipeline and observed dramatic improvement in immune responses and anti-tumor activity."
Specifically, the research team demonstrated that a change in the Fc region can significantly improve the cross-talk between two immune cell types, such as antigen presenting cells (APCs) and T cells. This modification in the Fc region increases the duration and strength of interaction between the immune cells. In cancer immunotherapy, such an interaction is necessary to mount a potent immune response against cancer.
"These findings are at the core of our next-generation antibody programs, which have moved at an incredible speed from the drawing boards to being clinic ready in about 15 months, a testament to our strategy built on innovation and speed," said Alex Duncan, PhD, Chief Technology Officer and Head of Research. "These findings provide a foundation for developing best-in-class antibodies optimized to improve response rates and durability of response for patients with cancer."
For more details please see the publication here www.cell.com/cancer-cell/fulltext/S1535-6108(18)30219-8.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing a number of combination approaches that leverage a broad repertoire of antibody therapeutics and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com; information that may be important to investors will be routinely posted on our website.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the Company's planned IND filings and the enhanced function of certain antibodies in the Company's pipeline. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
Cision View original content with multimedia:www.prnewswire.com/news-releases/...cancer-cell-300664692.html
SOURCE Agenus Inc.
In den letzten Wochen gute News geliefert, werde mal hübsch aufstocken hier.
abgeht.3 Mal hinter einander auf Tagestief geschlossen,seit Wochen im MINUS.Mal schauen wann das Elend zu Ende geht..
Meines Erachtens kann hier innerhalb von ein paar Wochen wieder eine Verdoppelung möglich werden...
Nur meine Meinung!
Nur meine Meinung!
wirklich gruselig..
Vielleicht komme ich bei 2,30 mal wieder an Bord
Vielleicht komme ich bei 2,30 mal wieder an Bord
(Verkleinert auf 39%)
|
Neueste Beiträge aus dem Agenus Inc Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
4 | 274 | Neustart mit "frischem Kapital" | Heron | gaedda | 27.04.24 10:41 | |
| 3 | Agenus - neue WKN - es tut sich was | moneywork4me | Balu4u | 26.04.24 16:37 | ||
| Agenus 4,5 $ | Berndthc | 25.04.21 11:25 | ||||
| 130 | Ist was durchgesickert?? | Friends | alice.im.börsenland | 16.04.12 15:13 | ||
| 5 | Antigenics auf Einstiegsniveau? | xpfuture | Friends | 10.06.09 19:52 |
